主页 > 医学动态 >
【drug-news】镇痛药具有不同的心脏病风险（sina采
July 16, 2007
Pain drugs have different heart risks
By Will Boggs, MD
NEW YORK (Reuters Health) - The various anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, which are used to treat arthritis and other painful conditions, differ in the risks of heart attacks and stroke, according to a report in the Annals of the Rheumatic Diseases. Much of the difference seems to depend on how the drug interacts with aspirin, which is commonly given to prevent heart attacks.
"Traditional NSAIDs, and ibuprofen in particular, do have the potential to interact with the effects of aspirin," Dr. Michael E. Farkouh from Mount Sinai School of Medicine, New York told Reuters Health. "For patients at high (risk of heart attack and stroke), this interaction is serious since these patients require aspirin to prevent" these cardiovascular problems.
Farkouh and associates investigated cardiovascular outcomes in high-risk patients with arthritis treated with ibuprofen, naproxen, or lumiracoxib. Their analyses were based on data for over 18,000 participants in the TARGET (Therapeutic Arthritis Research and Gastrointestinal Event Trial) study.
Among patients taking low-dose aspirin, the risk of death, heart attack, or stroke at 1 year was more common with ibuprofen than with lumiracoxib, the authors report, but did not differ significantly between naproxen and lumiracoxib.
Among patients not taking low-dose aspirin, there was no difference in outcomes between ibuprofen and lumiracoxib, the report indicates, but there were fewer cardiovascular events among those taking naproxen rather than lumiracoxib.
"For patients at high cardiovascular risk, naproxen is the drug of choice," Farkouh said. "It has the best overall safety record."
SOURCE: Annals of the Rheumatic Diseases, June 2007. 本人认领翻译，如在24小时未能提交，请其它战友认领。 Pain drugs have different heart risks
镇痛药的心脏病风险有所差异
By Will Boggs, MD
NEW YORK (Reuters Health) - The various anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, which are used to treat arthritis and other painful conditions, differ in the risks of heart attacks and stroke, according to a report in the Annals of the Rheumatic Diseases. Much of the difference seems to depend on how the drug interacts with aspirin, which is commonly given to prevent heart attacks.
纽约（路透社健康新闻）-据发表在《风湿病年报》文章报告，用于治疗关节炎和其它疼痛症状的不同抗炎药物（NSAIDs，非甾体抗炎药），如布洛芬和萘普生，具有不同的心脏病发作和卒中风险。许多不同似乎依赖于药物与阿司匹林的相互作用，后者常用于预防心脏病发作。
"Traditional NSAIDs, and ibuprofen in particular, do have the potential to interact with the effects of aspirin," Dr. Michael E. Farkouh from Mount Sinai School of Medicine, New York told Reuters Health. "For patients at high (risk of heart attack and stroke), this interaction is serious since these patients require aspirin to prevent" these cardiovascular problems.
“传统的非甾体抗炎药，特别是布洛芬，确实具有与阿司匹林相互作用的可能。”纽约西奈山医学院Michael E. Farkouh博士告诉记者说。“对于心脏病发作和卒中高风险患者来说，这种相互作用是严重的，因为这些患者需要服用阿司匹林来预防这些心血管疾病。”
Farkouh and associates investigated cardiovascular outcomes in high-risk patients with arthritis treated with ibuprofen, naproxen, or lumiracoxib. Their analyses were based on data for over 18,000 participants in the TARGET (Therapeutic Arthritis Research and Gastrointestinal Event Trial) study.
Farkouh及其同事调查了患有关节炎的高危患者应用布洛芬、萘普生或氯美昔布治疗的心血管结果。他们的分析基于参与TARGET（治疗关节炎研究和胃肠道事件试验）研究的18000多名患者的数据。
Among patients taking low-dose aspirin, the risk of death, heart attack, or stroke at 1 year was more common with ibuprofen than with lumiracoxib, the authors report, but did not differ significantly between naproxen and lumiracoxib.
作者报告称，在服用低剂量阿司匹林的患者中，同时服用布洛芬的患者一年内出现死亡、心脏病发作或卒中的风险较同服氯美昔布的患者更为常见。但服用萘普生和氯美昔布的患者之间没有显著性差异。
Among patients not taking low-dose aspirin, there was no difference in outcomes between ibuprofen and lumiracoxib, the report indicates, but there were fewer cardiovascular events among those taking naproxen rather than lumiracoxib.
报告指出，在没有服用低剂量阿司匹林的患者中，服用布洛芬和氯美昔布的患者的结果没有区别，但服用萘普生的患者与服用氯美昔布的患者相比，他们发生较少的心血管事件。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-28 05:11
医学,生命科学网